Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lieitinib plus bevacizumab and chemotherapy for EGFR L858R NSCLC with brain metastases (Phase II)
ChiCTR2600127374Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of limertinib and bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-Free Survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
limertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600127374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127374.